Article

Validation of an in vitro diagnostic test for endometriosis: impact of confounding medical 2 conditions and lesion location 3 Elza Daoud¹, David F. Archer², Bárbara Herranz-Blanco^{1,*} 4 ¹ Chemo Research, Madrid, Spain, 5 2 Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, Virginia, USA. 6 Correspondence: barbara.herranz@exeltis.com Abstract: With the aim to shorten the time for diagnosis and accelerate access to correct manage-8 ment, a non-invasive diagnostic test for endometriosis was developed and validated. The IVD test

9 combines an ELISA test kit to quantify CA125 and BDNF concentrations in serum and a data treat-10 ment algorithm hosted in medical software processing results from the ELISA test and responses to 11 six clinical variables. Serum samples and clinical variables extracted from psychometric question-12 naires from 77 patients were collected from the Oxford Endometriosis CaRe Centre biobank (UK). 13 Case/control classification was performed based on laparoscopy and histological verification of the 14 excised lesions. Biomarkers serum concentrations and clinical variables were introduced to the soft-15 ware, which generates the qualitative diagnostic result ("positive" or "negative"). This test allowed 16 the detection of 32% of cases with superficial endometriosis, which is an added value given the 17 limited efficacy of existing imaging techniques. Even in the presence of various confounding medi-18 cal conditions, the test maintained a specificity of 100%, supporting its suitability for use in patients 19 with underlying medical conditions. 20

Keywords: In vitro diagnostic test; endometriosis; validation; lesion location; superficial endome-21 triosis; confounding conditions. 22

1. Introduction

Endometriosis is a progressive, estrogen-dependent disease that affects approxi-25 mately 10% of women of reproductive age [1]. It is characterized by the presence of en-26 dometrial-like tissue outside the uterus, commonly affecting the pelvic cavity, ovaries, 27 fallopian tubes, and other surrounding structures[2]. These lesions result in a chronic 28 inflammatory response, which can lead to the formation of scar tissue and adhesions[3]. 29 The clinical presentation of endometriosis can be very diverse, with a wide range of 30 symptoms, including chronic non-menstrual pelvic pain, dysmenorrhea, dysuria, infer-31 tility, and many others; with the onset of symptoms usually occurring during adoles-32 cence[1,4]. The severity and manifestation of symptoms can be influenced by various 33 factors, including the location and extent of the endometrial implants, hormonal fluctua-34 tions, and individual pain thresholds [5,6]. Also, symptoms often overlap with those of 35 various other conditions [7,8]. Although imaging techniques such as transvaginal ultra-36 sound (TVUS) and magnetic resonance imaging (MRI) have been shown to accurately 37 diagnose some endometriosis cases, these are usually limited to more severe stages of 38 the disease[9,10]. Laparoscopy, with or without histological confirmation, remains the 39 gold standard for diagnosing endometriosis, but its invasive nature contributes to diag-40 nostic delays [1–3,11]. Therefore, despite its high prevalence, accurately diagnosing en-41 NOTE: This preprint reports demonstrance in an analytic manage by the review that smith and in the provided in the second statement and 42

a diagnostic delay of 4-11 years [7,12]. This delay hinders the identification of early



Copyright: © 2024 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/license s/by/4.0/).

1

24

43

2 of 14

44

45

46

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

stages, allowing the condition to progress, leading to increased severity, fibrosis, and potential infertility [13,14]. Developing a non-invasive diagnostic test for endometriosis becomes crucial in order to obviate the delay in diagnosis [15,16].

Prior studies have delved into an extensive array of biomarkers, highlighting the 47 complexity of understanding endometriosis. CA125, a widely recognized glycoprotein, 48 has been a focal point in research due to its association with various gynecological con-49 ditions, including endometriosis [17–19]. Despite its usefulness, the lack of specificity 50 and limited sensitivity as a standalone marker, along with its utility being limited to late 51 stages of the disease, has underscored the need for complementary biomarkers. Brain-52 derived neurotrophic factor (BDNF), known for its involvement in neuroplasticity and 53 neuronal survival, has emerged as a promising candidate, with studies demonstrating 54 elevated levels in patients with endometriosis compared to healthy controls [11,20,21]. 55 However, the lack of specificity among individual biomarkers emphasizes the necessity 56 of a comprehensive diagnostic approach integrating multiple markers to enhance accu-57 racy and reliability in endometriosis detection. 58

Recently, we have developed a diagnostic treatment algorithm that combines CA125 and BDNF measurements with six pertinent clinical variables: patient's surgical history related to endometriosis, the manifestation of painful periods as a leading symptom for endometriosis referral, the intensity of menstrual pain during the previous cycle, the age at the onset of intercourse-related pain, the age at the initiation of regular painkiller usage, and the age at the initial diagnosis of an ovarian cyst. CA125, BDNF, and the six clinical factors were integrated into the final logistic regression model, achieving an AUC of 0.867, sensitivity of 51.5%, and specificity of 95.6% [22].

The influence of confounding conditions on the final diagnosis of endometriosis using this test was challenged. This is because multiple conditions, gynecological (for instance, adenomyosis [23–26], pelvic inflammatory disease (PID) [27–29], uterine fibroids [29–31] and ovarian cysts [29,32]) and non-gynecological (for instance, inflammatory bowel disease (IBD) [33] or rheumatoid arthritis [34–36], asthma [37], anxiety and depression [38–40]) could affect the levels of CA125 and BDNF.

The primary aim of this study was to validate the diagnostic performance of the test in endometriosis patients while also discerning the specific subgroup of patients in which the test demonstrates superior performance. The secondary aim was to further investigate how confounding conditions influence CA125 and BDNF and whether or not the performance of the test is affected.

2. Results

2.1. Diagnostic performance by endometriosis lesion type

One hundred percent of controls from the validation dataset were correctly diagnosed 80 (negative) with the IVD test, based on the threshold established in the development da-81 taset. With this, a sensitivity (after weighing for disease stages) of 46.2% (95% CI: 25.5-82 66.8%) and a specificity of 100% (95% CI: 86.7-100%) was obtained. The accuracy was 83 64.1% (95% CI: 50.4-77.8%) and the AUC was 0.758 (95% CI: 0.650-0.867). To understand 84 in which subgroup of endometriosis patients the test works best, i.e., is capable of detect-85 ing the highest number of cases, patients were separated in subgroups by lesion types. 86 First, the association between the stages of endometriosis and the types of endometriosis 87 lesions was examined using Pearson's chi-squared test. The analysis revealed a signifi-88 cant association ($\chi^2 = 765.76$, df = 25, p < 0.001), indicating a strong relationship between 89 the rASRM stages classification of endometriosis and classification by types of lesions. 90 The contingency table (Table 1) provides insight on how lesion types are distributed by 91 endometriosis rASRM stage for patients of pooled development and validation datasets. 92

3 of 14

rASRM stage	Stage I	Stage II	Stage III	Stage IV	Unclassified
lesion type	(n=81)	(n=30)	(n=34)	(n=41)	(n=2)
C-section	0	0	0	0	2
DIE	7	17	7	9	0
Endometrioma	5	0	16	7	0
Endometrioma	0	3	10	20	0
+ DIE					
Superficial	66	10	1	2	0
Unclassified	3	0	0	3	0

Superficial lesions are observed mostly in stage I (81.5%). Extended lesions (endometrioma+DIE) are as expected mostly observed in stage IV. 94

 Table 1. Contingency table for the distribution of lesion types by endometriosis rASRM stages.

97 98

Sensitivity was investigated by lesion type. Results (as reported in table 2) indicate that 99 the IVD test successfully identified around half of the cases of DIE and endometrioma. 100 Furthermore, with a sensitivity of 69.70%, the IVD test demonstrate that the test works 101 best in identifying cases of DIE+endometrioma. Interestingly, 32% of cases of superficial 102 endometriosis were correctly identified with the test. As expected, the two cases of endometriosis located within c-section scars could not be identified with the test (different 104 pathophysiology, as described above). 105

Gynecological Condition	Number of controls in development data (n=68)	Number of controls in valida- tion data (n=25)	Total number of controls (n=93)
Ovarian cysts	28	11	39
Uterine fibroids	7	3	10
Adenomyosis	0	1	1
PCOS	16	8	24
Pelvic inflammatory disease	4	2	6
At least one condition	40	19	55

106 107

Table 2. Distribution of cases, number of true positive and sensitivity by lesion type in both devel-108opment and validation datasets.109

110

An ANOVA was conducted to examine the differences in CA125 values among various 111 types of endometriosis lesions in the pooled datasets (development and validation da-112 tasets, figure 1). The results revealed a significant effect of lesion type on CA125 levels 113 (F(5, 275) = 26.162, p < 0.001). Post hoc analyses indicated that the differences were statis-114 tically significant (p < 0.001) across the various lesion types. The Tukey multiple compar-115 ison of means at a 95% family-wise confidence level revealed several significant differ-116 ences between the types of lesions in terms of CA125 levels: comparing endometrioma to 117 DIE, there was a statistically significant difference (p<0.01). Additionally, the mean CA125 118 level (56.05 IU/mL, SD=39.35) were higher for endometrioma than for DIE (32.28 IU/mL, 119 SD=32.69) (p=0.01). Moreover, the mean CA125 level for endometrioma + DIE (67.69 120

IU/mL, SD=45.49) was higher than the mean CA125 level for DIE (mean=32.28 IU/mL, 121 SD=32.69) (p<0.001). Lower CA125 levels were observed for superficial lesions 122 (mean=19.55 IU/mL, SD=24.74) than for endometrioma (p<0.001), DIE (p=0.02) and endo-123 metrioma + DIE (p<0.001). An ANOVA conducted on BDNF values across different lesion 124 types did not show any significant differences of BDNF across different types of lesions 125 (p=0.094). This suggests that the improved sensitivity for DIE+endometrioma lesions is 126 likely to be due to higher levels of CA125 in those lesions, contributing to a higher rate of 127 true positive results in cases with those lesions. 128




Figure 1. Comparison of CA125 levels between lesion types.

2.2. Interference of potentially confounding medical conditions

As shown in table 3, despite 76% (19 out of 25 controls) of controls in the validation dataset having at least one condition that could elevate CA125, the specificity of the diagnostic test was 100%.

Gynecological Condi- tion	Number of controls in development data (n=68)	Number of controls in validation data (n=25)	Total number of controls (n=93)
Ovarian cysts	28	11	39
Uterine fibroids	7	3	10
Adenomyosis	0	1	1
PCOS	16	8	24
Pelvic inflammatory disease	4	2	6
At least one condition	40	19	55

Table 3. Distribution of gynecological conditions known to elevate CA125 across controls.

Two-way ANOVA with EndoState (Cases/controls) and each confounding condition as140predictors was run on CA125 levels in the pooled datasets. For ovarian cysts, the ANOVA141revealed the main effect of EndoState (F = 32.97, p<0.001) and Ovarian cyst condition (F =</td>14222.65, p<0.001) on CA125 levels. Individuals with ovarian cysts had higher CA125 values</td>143than individuals without ovarian cysts (p<0.001). No interaction between both predictors</td>144

130 131

129

132

133 134

137 138

5 of 14

160

was reported. For uterine fibroids (UF), a main effect for condition on CA125 was ob-145 served (F=11.22, p<0.001) as well as an expected main effect for EndoState (F=15.30, 146p<0.001). No interaction between both predictors was reported. Individuals with uterine 147 fibroids had higher CA125 values than individuals without uterine fibroids (p<0.001). 148 Two-way analysis of variance (ANOVA) with EndoState (Cases/controls) and each con-149 founding condition as predictors was run on BDNF in pooled datasets. For Chronic fa-150 tigue only, a main effect was observed for EndoState (F=5.75, p=0.017) and an interaction 151 between EndoState and the condition (F=4.20, p=0.04). Pairwise comparisons revealed 152 that cases without chronic fatigue have higher BDNF values than controls with chronic 153 fatigue (mean difference=6.06, p=0.04). 154

The performance of the diagnostic test was determined in the validation dataset exclud-155ing each confounding condition at a time. Results, as shown in Table 4, indicate that the156sensitivity values when excluding conditions stay within the 95% CI of the original sensitivity (all conditions included) between 34.3 and 62.9, meaning that no condition critically affects the ability of the test of detecting cases.157

Left out condition	Number of subjects by condition	Sensi- tivity	95% CI lower limit	95% CI upper limit
All (no data left out)	0	48,5	34,3	62,9
Ovarian cyst	27	50,8	34,1	67,4
Uterine fibroids	7	45,8	31,3	61
Adenomyosis	2	46,1	32	60,8
Inflammatory Bowel Disease	2	46,1	32	60,8
Depression requiring medication or ther- apy	29	34,3	18,9	53,4
Anxiety requiring medication or therapy	20	37,9	22,6	55,8
Pelvic Inflammatory Disease	6	49,8	35,8	63,9
Eczema	16	55,6	39,6	70,5
Polycystic Ovary Syndrome	17	48,6	33,1	64,3
Interstitial cystitis	7	48,9	33,9	64
Asthma	23	48,8	32,1	65,7
Chronic fatigue syndrome - Myalgic en- cephalomyelitis	1	47,6	33,4	62,2
Fibromyalgia	1	47,6	33,4	62,2
Irritable Bowel Syndrome	17	42,7	27,2	59,6
Migraine	22	42	26	59,6
Glandular fever	5	47,9	33,5	62,6
Ulcerative colitis	2	46,1	32	60,8
High blood pressure	4	47,9	33,5	62,6

Table 4. Performance of the IVD test (validation dataset) excluding each medical condition at a time.

161 162

164

163

6 of 14

166

203

204

3. Discussion

The newly developed test for endometriosis demonstrates a high specificity of 100%, 167 suggesting its potential use as a rule-in test in clinical practice. This diagnostic test could 168 significantly contribute to the initial diagnostic workup, effectively confirming the pres-169 ence of endometriosis and providing clinicians with a reliable tool for early detection and 170 intervention. Moreover, the test demonstrates an encouraging ability to identify superfi-171 cial lesions of endometriosis, as evidenced by the reported sensitivity of 32 %. This feature 172 is of particular significance considering the constraints associated with the ability of alter-173 native diagnostic methods to detect superficial lesions: superficial endometriosis, charac-174terized by its subtle and less invasive nature, presents unique challenges for detection 175 using ultrasound or MRI. Peritoneal implants invading less than 5 mm of depth from the 176 peritoneal surface are often invisible on MRI [10]. These imaging techniques may struggle 177 to capture the nuanced characteristics of these lesions due to their limited ability to visu-178 alize subtle changes in the peritoneum and pelvic surfaces [42]. Additionally, the lack of 179 specific imaging markers or distinguishing features that differentiate superficial lesions 180 from surrounding healthy tissue makes it difficult to accurately identify these lesions us-181 ing standard imaging modalities. The intricate anatomical location of superficial lesions, 182 often nestled within complex pelvic structures, further contributes to the complexity of 183 their detection, as these areas may be challenging to access and visualize accurately using 184traditional imaging approaches [43]. By enabling the identification of superficial lesions, 185 the test offers clinicians an essential means of identifying cases that would otherwise have 186 gone undetected, thereby facilitating a more comprehensive and accurate patient man-187 agement. 188

Also, the test demonstrated a relatively high sensitivity of 69.70% in detecting endo-189 metrioma+ DIE lesions, possibly correlated to patients with those lesions having the high-190 est level of CA125 compared to other types of lesions. Endometrioma, an endometriosis-191 related ovarian cyst, often exhibits elevated CA125 levels due to its involvement of the 192 ovaries and resulting inflammatory processes. The higher mean CA125 level observed in 193 this group aligns with prior studies [44]. The observed higher mean CA125 level in the 194 endometrioma + DIE lesions compared to the DIE alone, along with the lowest CA125 195 levels in the superficial endometriosis, suggest that CA125 expression increases with the 196 extent of the disease (i.e., the extent of tissue involvement and disease spread). 197

Even in the presence of various confounding medical conditions, the test maintains198its robustness and reliability, emphasizing its independence from potential confounding199factors with 100% of the controls being negative. This characteristic supports its suitability200for use in various clinical settings, irrespective of the patient's medical history, thereby201ensuring its applicability without contraindications.202

4. Materials and Methods

4.1. Patients' characteristics and classification

The current report is a prospective analysis study using biobank samples. A total of 205 281 samples extracted from the renowned Oxford Endometriosis CaRe Centre biobank in 206 the UK were included for the development (I) and external validation (II) studies. The 207 biobank's repository comprised meticulously curated serum samples and comprehensive 208 clinical information derived from pre-surgical assessments and post-operative procedures 209 of patients within reproductive age (18–50 years old) undergoing laparoscopy because of 210 a suspicion of endometriosis. Patients were classified as cases or controls based on lapa-211 roscopy and thorough evaluation of histological findings. After undergoing laparoscopy, 212 patients diagnosed with endometriosis were categorized into stages according to the re-213 vised American Society of Reproductive Medicine (rASRM) classification. Patients who 214 had not used hormones in the 3 months prior to surgery were selected. 215

136 endometriosis cases and 68 controls were included in the development study 216 (n=204). For the validation study (n=77), 52 cases and 25 controls were included. The 217

7 of 14

demographic characteristics of those patients are available in Table 5. The experimental218procedures received approval from the Ethics Committee of CEIm HM Hospitales (codes:21919.05.1411-GHM and 22.03.2001-GHM).220221221

	Development study (I)		Validation study (I	
	Controls	Cases	Controls	Cases
	N=68	N=136	N=25	N=52
Age years (mean ± SD)	33.5 (5.96)	35.6 (6.42)	35 (6.44)	35 (6.47)
BMI (mean ± SD)	25.38 (4.63) 26.46 (5.32)		26 (5.23)	26 (5.14)
rASRM classification				
I–II	-	68 (50%)	-	42 (81%)
III–IV	-	68 (50%)	-	7 (13%)
Missing information		-	-	3 (6%)

Table 5. Demographic characteristics and rASRM classification of the patients in the development (I) and validation (II) studies.

4.2. Lesion location and subtyping

Imaging findings and surgical examinations have been reported for each subject in-227 cluded in the study. Endometriosis lesions were investigated by location. From these find-228 ings, endometriosis lesions were classified into subgroups according to their location in 229 the ovaries and the peritoneal cavity: superficial (< 5 mm depth), endometrioma, and/or 230 deep infiltrative endometriosis (DIE). Specifically, the designation "superficial" was as-231 signed when only superficial endometriosis lesions were identified in the ovaries or peri-232 toneal cavity. The classification of "endometrioma" was used when endometriomas were 233 detected in the ovaries, either with or without accompanying superficial endometriosis. 234 In cases where infiltrative lesions were observed in the peritoneal cavity, with or without 235 associated superficial endometriosis, lesions were classified as "DIE". Moreover, the "en-236 dometrioma + DIE" classification was assigned when both DIE and endometriomas were 237 found in the peritoneal cavity, with or without superficial endometriosis. While endome-238 triosis is thought to be caused by retrograde menstruation, the most likely cause of cae-239 sarean section (c-section) scar endometriosis is iatrogenic implantation. Due to this differ-240 ent aetiology, 2 patients with c-section scar endometriosis were misclassified as they 241 should fall under a different category than endometriosis with spontaneous implantation. 242 The distributions of cases of the development and validation studies by lesions type are 243 described in Table 6. 244

245

222 223

8 of 14

Endometriosis Classification	Development study (I) N=136	Validation study (II) N=52
Superficial	54 (39.7%)	24 (46.2%)
Endometrioma	25 (18.4%)	3 (5.8%)
DIE	28 (20.6%)	13 (25%)
DIE + endometri- oma	25 (18.4%)	8 (15.4%)
Unclassified	4 (2.9%)	2(3.8%)
C-section scar	0	2 (3.8%)

Table 6. Classification of endometriosis cases according to lesion location.

4.3. Confounding disease screening

Patients were asked to fill out a presurgical survey including a question to indicate 252 the absence/presence of confounding medical conditions from a list. They were asked: 253 please mark whether you have had any of the following medical conditions, and at what 254 age you were first diagnosed by a doctor (please tick all that apply)" and were given the 255 list of medical conditions. Patients were also asked to indicate whether they were affected 256 by other unlisted medical conditions. This survey was administered to patients in one of 257 its 3 versions: version #1 did not list 3 medical conditions: Anxiety (1), cardiovascular dis-258 ease (2) and high blood pressure (3). These conditions were only listed in questionnaires 259 #2 and #3. Versions #2 and #3 were responded by 141 out of 190 patients included in the 260 development study (14 patients did not answer to this question out of 204) and 64 out of 261 77 patients included in the validation study. For completeness, imaging and surgical find-262 ings were used to further identify patients with gynaecological conditions. 263

Table 7 depicts the prevalence of the confounding conditions in patients included in264the development and validation studies.265

Confounding condition	Prevalence in devel-	Prevalence in validation
	opment study	study
Anxiety requiring medication or ther-	39/141 (28%)	20/64 (31%)
apy		
Asthma	42/190 (22%)	23/77 (30%)
Adenomyosis	7/190 (3.7%)	2/77 (2.6%)
Cardiovascular disease	0	0
Crohn's disease	0	0
Chronic fatigue syndrome - Myalgic	10/190 (5.2%)	1/77 (1.3%)
encephalomyelitis		
Depression requiring medication or	68/190 (35.8%)	29/77 (38%)
therapy		
Diabetes requiring diet control	3/190 (1.6%)	0
Diabetes requiring insulin or tablets	1/190 (0.5%)	0
Eczema	32/190 (16.8%)	16/77 (21%)
Uterine fibroids	28/190 (9.5%)	7/77 (9.1%)
Fibromyalgia	4/190 (2%)	1/77 (1.3%)

246 247

248

249 250



9 of 14

Graves's disease 0 0 Hashimoto's disease 0 0 High blood pressure 9/141 (6%) 4/64 (6.2%) Irritable bowel syndrome 43/190 (23%) 17/77 (22%) Interstitial Cystitis 12/190 (62.5%) 7/77 (9%) Migraine 51/190 (27%) 22/77 (28.6%) Mitral valve prolapse 2/190 (1%) 0 Multiple sclerosis 2/190 (1%) 0 Ovarian cysts 93/190 (49%) 27/77 (35.1%) Pelvic inflammatory disease 13/190 (6.84%) 6/77 (7.8%) Polycystic ovarian syndrome 32/190 (16.8%) 0 Sjogren's syndrome 0 1/77 (1.3%) Systemic lupus erythematosus 0 0 Thyroid disease 3/190 (1.6%) 0 Ulcerative colitis 1/190 (0.5%) 2/77 (2.6%)	Glandular fever	17/190 (8.9%)	5/77 (6.5%)
High blood pressure9/141 (6%)4/64 (6.2%)Irritable bowel syndrome43/190 (23%)17/77 (22%)Interstitial Cystitis12/190 (62.5%)7/77 (9%)Migraine51/190 (27%)22/77 (28.6%)Mitral valve prolapse2/190 (1%)0Multiple sclerosis2/190 (1%)0Ovarian cysts93/190 (49%)27/77 (35.1%)Pelvic inflammatory disease13/190 (6.84%)6/77 (7.8%)Polycystic ovarian syndrome32/190 (16.8%)17 (22.1%)Rheumatoid arthritis00Sjogren's syndrome01/77 (1.3%)Systemic lupus erythematosus00Thyroid disease3/190 (1.6%)0	Graves's disease	0	0
Irritable bowel syndrome 43/190 (23%) 17/77 (22%) Interstitial Cystitis 12/190 (62.5%) 7/77 (9%) Migraine 51/190 (27%) 22/77 (28.6%) Mitral valve prolapse 2/190 (1%) 0 Multiple sclerosis 2/190 (1%) 0 Ovarian cysts 93/190 (49%) 27/77 (35.1%) Pelvic inflammatory disease 13/190 (6.84%) 6/77 (7.8%) Polycystic ovarian syndrome 32/190 (16.8%) 17 (22.1%) Rheumatoid arthritis 0 0 Sjogren's syndrome 0 1/77 (1.3%) Systemic lupus erythematosus 0 0 Thyroid disease 3/190 (1.6%) 0	Hashimoto's disease	0	0
Interstitial Cystitis 12/190 (62.5%) 7/77 (9%) Migraine 51/190 (27%) 22/77 (28.6%) Mitral valve prolapse 2/190 (1%) 0 Multiple sclerosis 2/190 (1%) 0 Ovarian cysts 93/190 (49%) 27/77 (35.1%) Pelvic inflammatory disease 13/190 (6.84%) 6/77 (7.8%) Polycystic ovarian syndrome 32/190 (16.8%) 17 (22.1%) Rheumatoid arthritis 0 0 Sjogren's syndrome 0 1/77 (1.3%) Systemic lupus erythematosus 0 0 Thyroid disease 3/190 (1.6%) 0	High blood pressure	9/141 (6%)	4/64 (6.2%)
Migraine 51/190 (27%) 22/77 (28.6%) Mitral valve prolapse 2/190 (1%) 0 Multiple sclerosis 2/190 (1%) 0 Ovarian cysts 93/190 (49%) 27/77 (35.1%) Pelvic inflammatory disease 13/190 (6.84%) 6/77 (7.8%) Polycystic ovarian syndrome 32/190 (16.8%) 17 (22.1%) Rheumatoid arthritis 0 0 Sjogren's syndrome 0 1/77 (1.3%) Systemic lupus erythematosus 0 0 Thyroid disease 3/190 (1.6%) 0	Irritable bowel syndrome	43/190 (23%)	17/77 (22%)
Mitral valve prolapse2/190 (1%)0Multiple sclerosis2/190 (1%)0Ovarian cysts93/190 (49%)27/77 (35.1%)Pelvic inflammatory disease13/190 (6.84%)6/77 (7.8%)Polycystic ovarian syndrome32/190 (16.8%)17 (22.1%)Rheumatoid arthritis00Sjogren's syndrome01/77 (1.3%)Systemic lupus erythematosus00Thyroid disease3/190 (1.6%)0	Interstitial Cystitis	12/190 (62.5%)	7/77 (9%)
Multiple sclerosis 2/190 (1%) 0 Ovarian cysts 93/190 (49%) 27/77 (35.1%) Pelvic inflammatory disease 13/190 (6.84%) 6/77 (7.8%) Polycystic ovarian syndrome 32/190 (16.8%) 17 (22.1%) Rheumatoid arthritis 0 0 Sjogren's syndrome 0 1/77 (1.3%) Systemic lupus erythematosus 0 0 Thyroid disease 3/190 (1.6%) 0	Migraine	51/190 (27%)	22/77 (28.6%)
Ovarian cysts 93/190 (49%) 27/77 (35.1%) Pelvic inflammatory disease 13/190 (6.84%) 6/77 (7.8%) Polycystic ovarian syndrome 32/190 (16.8%) 17 (22.1%) Rheumatoid arthritis 0 0 Sjogren's syndrome 0 1/77 (1.3%) Systemic lupus erythematosus 0 0 Thyroid disease 3/190 (1.6%) 0	Mitral valve prolapse	2/190 (1%)	0
Pelvic inflammatory disease13/190 (6.84%)6/77 (7.8%)Polycystic ovarian syndrome32/190 (16.8%)17 (22.1%)Rheumatoid arthritis00Sjogren's syndrome01/77 (1.3%)Systemic lupus erythematosus00Thyroid disease3/190 (1.6%)0	Multiple sclerosis	2/190 (1%)	0
Polycystic ovarian syndrome32/190 (16.8%)17 (22.1%)Rheumatoid arthritis00Sjogren's syndrome01/77 (1.3%)Systemic lupus erythematosus00Thyroid disease3/190 (1.6%)0	Ovarian cysts	93/190 (49%)	27/77 (35.1%)
Rheumatoid arthritis00Sjogren's syndrome01/77 (1.3%)Systemic lupus erythematosus00Thyroid disease3/190 (1.6%)0	Pelvic inflammatory disease	13/190 (6.84%)	6/77 (7.8%)
Sjogren's syndrome01/77 (1.3%)Systemic lupus erythematosus00Thyroid disease3/190 (1.6%)0	Polycystic ovarian syndrome	32/190 (16.8%)	17 (22.1%)
Systemic lupus erythematosus00Thyroid disease3/190 (1.6%)0	Rheumatoid arthritis	0	0
Thyroid disease 3/190 (1.6%) 0	Sjogren's syndrome	0	1/77 (1.3%)
	Systemic lupus erythematosus	0	0
Ulcerative colitis 1/190 (0.5%) 2/77 (2.6%)	Thyroid disease	3/190 (1.6%)	0
	Ulcerative colitis	1/190 (0.5%)	2/77 (2.6%)

Table 7. Prevalence of confounding conditions in the development and validation datasets.

270 271 272

273 274

275

284

285

286

287

288

289

290

291 292

293

268

269

4.4. Blood sample collection and biomarkers measurement

The specimens were gathered and managed with explicit patient consent, following 276 the guidelines outlined in the Standard Operating procedures of the World Endometriosis 277 Research Foundation [41]. Before the collection of blood, patients were instructed to main-278 tain a minimum fasting period of 10 hours. The serum samples were then preserved in 279 the biobank at temperatures as low as -80 $^{\circ}$ C for a duration of up to 5 years, after which 280 they were transferred to the designated laboratory for analysis. The ELISA utilized in this 281 in vitro diagnostic test functions as a solid-phase sandwich enzyme-immunoassay for the 282 precise determination of BDNF and CA125 levels within human serum [22]. 283

4.5. Data treatment algorithm

All the necessary input parameters, including serum CA125, serum BDNF, and clinical variables were gathered. Subsequently, laboratory technicians input this data into the IVD test diagnostic medical software, which houses the data treatment algorithm. The algorithm processed the input and generated outcomes, classifying them as either positive or negative based on whether the value exceeded or fell below the predetermined threshold value, respectively.

4.6. Statistical analysis

Statistical analysis was conducted utilizing R software, version 4.1.3, provided by the 294 R Foundation for Statistical Computing in Vienna, Austria. The statistical significance 295 level was set at p < 0.05, indicating a threshold below which results were considered statistically significant. In the validation study, the IVD test software was utilized to compute 297 algorithm scores and their corresponding outcomes. These outcomes were delineated as 298 positive diagnosis when the score surpassed the defined cut-off, and negative diagnosis 299 when the score fell below the defined cut-off. Specifically, the validation study's 300

10 of 14

sensitivity and specificity were expected to align with or exceed the lower limits of the 301 sensitivity and specificity 95% confidence intervals outlined in the algorithm development 302 study: an AUC of 0.867 with a sensitivity of 51.5% (42.8 - 60.1) at a specificity of 95.6% 303 (86.8 - 98.9%) as reported by Herranz et al. To assess the IVD test clinical performance, the 304 results of the primary performance parameters (sensitivity and specificity) were con-305 trasted with the acceptance criteria values established during the development study. To 306 ensure equitable representation of both the low-stage and high-stage groups, the out-307 comes in the validation were appropriately weighted. 308

To further elucidate the performance of the IVD test, the sensitivity for each endome-309 triosis classification, with the values specified alongside their respective 95% CI are re-310 ported for the distinct subgroups based on lesion types. For a more comprehensive assess-311 ment of test's efficacy over a larger sample size, development and validation datasets were 312 pooled. Analysis was run on pooled dataset. BDNF values in pooled datasets followed a 313 normal distribution and CA125 values were arithmetically transformed to follow a normal 314 distribution. To investigate the effect of confounding diseases on biomarkers levels and 315 the performance of the test, only conditions with >1% prevalence in both datasets were 316 considered. A two-way ANOVA analysis was conducted to assess the effect of medical 317 conditions and EndoState (Cases/controls) on CA125 and BDNF, respectively, including 318 an interaction term. Only conditions showing significant main effects or interaction will 319 be reported. Furthermore, the performance of the algorithm on validation data was eval-320 uated after excluding each specific conditions, one at a time. 321

5. Conclusions

Overall, the high specificity of the test, coupled with its independence from potential 324 confounding medical conditions, position it as a valuable and reliable tool for the accurate 325 and timely diagnosis of endometriosis. 326

6. Patents

There is a patent resulting from the work reported in this manuscript.

Author Contributions: For research articles with several authors, a short paragraph specifying their 330 individual contributions must be provided. The following statements should be used "Conceptual-331 ization, E.D. and B-H.-B; methodology, E.D. and B-H.-B; software, E.D. and B-H.-B; validation, E.D. 332 and B-H.-B.; formal analysis, E.D. and B-H.-B; investigation, E.D. and B-H.-B; resources, E.D and B-333 H.-B.; data curation, E.D. and B-H.-B.; writing-original draft preparation, E.D.; writing-review 334 and editing, E.D., B.H.-B, D.A.; visualization, E.D.; supervision, B.H.; project administration, E.D. 335 and B-H.-B.; funding acquisition, E.D. and B-H.-B. All authors have read and agreed to the pub-336 lished version of the manuscript." Please turn to the <u>CRediT taxonomy</u> for the term explanation. 337 Authorship must be limited to those who have contributed substantially to the work reported. 338

Funding: Exeltis (represented by Chemo Research S.L.) has fully sponsored the studies.

Institutional Review Board Statement: The study was conducted in accordance with the Declara-340tion of Helsinki, and approved by the Institutional Review Board (or Ethics Committee) of CEIm341HM Hospitales (codes: 19.05.1411-GHM and 22.03.2001-GHM and date of approval: April 12th, 2022342

Informed Consent Statement: Informed consent was obtained from all subjects involved in the343study. The experimental procedures received approval from the Ethics Committee of CEIm HM344Hospitales (codes: 19.05.1411-GHM and 22.03.2001-GHM).345

Conflicts of Interest: The authors E.D. and B.H.-B. were employed by the company Exeltis (represented by Chemo Research S.L.). 347

349

346

339

322

323

327

328 329

11 of 14	4
----------	---

[1] Zondervan KT, Becker CM, Missmer SA. Endometriosis. New England Journal of Media 2020;382:1244–56. https://doi.org/10.1056/NEJMra1810764.	ine
[2] Bulun SE, Yilmaz BD, Sison C, Miyazaki K, Bernardi L, Liu S, et al. Endometriosis. Endocr 2019;40:1048–79. https://doi.org/10.1210/er.2018-00242.	lev
[3] Symons LK, Miller JE, Kay VR, Marks RM, Liblik K, Koti M, et al. The Immunopathophys ogy of Endometriosis. Trends in Molecular Medicine 2018;24:748- https://doi.org/10.1016/j.molmed.2018.07.004.	
[4] Brosens I, Gordts S, Benagiano G. Endometriosis in adolescents is a hidden, progressive a severe disease that deserves attention, not just compassion. Hum Reprod 2013;28:2026- https://doi.org/10.1093/humrep/det243.	
[5] Schliep KC, Mumford SL, Peterson CM, Chen Z, Johnstone EB, Sharp HT, et al. Pain typol- and incident endometriosis. Hum Reprod 2015;30:2427–38. https://doi.org/10.1093/ht rep/dev147.	
[6] Johnson NP, Hummelshoj L, Adamson GD, Keckstein J, Taylor HS, Abrao MS, et al. Wo Endometriosis Society consensus on the classification of endometriosis. Hum Reprod 2017;32:3 24. https://doi.org/10.1093/humrep/dew293.	
[7] Agarwal SK, Chapron C, Giudice LC, Laufer MR, Leyland N, Missmer SA, et al. Clinical di nosis of endometriosis: a call to action. Am J Obstet Gynecol 2019;220:354.e1-354.e https://doi.org/10.1016/j.ajog.2018.12.039.	0
[8] Speer LM, Mushkbar, Erbele T. Chronic Pelvic Pain in Women. American Family Physic 2016;93.	ian
[9] Alborzi S, Poordast T, Askary E, Javedanmehr M, Shahraki MH, Alborzi S, et al. Evaluat and comparison of the accuracy of transvaginal ultrasound and MRI for the diagnosis of deep tal endometriosis: A cross-sectional study. International Journal of Gynecology & Obstet 2023;161:586–93. https://doi.org/10.1002/ijgo.14554.	ec-
[10] Bruyere C, Maniou I, Habre C, Kalovidouri A, Pluchino N, Montet X, et al. Pelvic MRI Endometriosis: A Diagnostic Challenge for the Inexperienced Radiologist. How Much Experie Is Enough? Academic Radiology 2021;28:345–53. https://doi.org/10.1016/j.acra.2020.02.023.	
[11] Wang S, Duan H, Li B, Hong W, Li X, Wang Y, et al. BDNF and TrKB expression levels patients with endometriosis and their associations with dysmenorrhoea. Journal of Ovarian search 2022;15:35. https://doi.org/10.1186/s13048-022-00963-9.	
[12] Taylor HS, Kotlyar AM, Flores VA. Endometriosis is a chronic systemic disease: clinical cl lenges and novel innovations. Lancet 2021;397:839–52. https://doi.org/10.1016/S01	

12 of	14
-------	----

[13] Shim JY, Laufer MR. Adolescent Endometriosis: An Update. J Pediatr Adolesc Gynecol 2020;33:112–9. https://doi.org/10.1016/j.jpag.2019.11.011.	387 388
[14] Parasar P, Ozcan P, Terry KL. Endometriosis: Epidemiology, Diagnosis and Clinical Manage-	389
ment. Curr Obstet Gynecol Rep 2017;6:34–41. https://doi.org/10.1007/s13669-017-0187-1.	390
[15] Ahn SH, Singh V, Tayade C. Biomarkers in endometriosis: challenges and opportunities. Fer-	391
tility and Sterility 2017;107:523–32. https://doi.org/10.1016/j.fertnstert.2017.01.009.	392
[16] Nisenblat V, Bossuyt PMM, Farquhar C, Johnson N, Hull ML. Imaging modalities for the non-	393
invasive diagnosis of endometriosis. Cochrane Database Syst Rev 2016;2:CD009591.	394
https://doi.org/10.1002/14651858.CD009591.pub2.	395
 [17] Hirsch M, Duffy JMN, Deguara CS, Davis CJ, Khan KS. Diagnostic accuracy of Cancer Antigen 125 (CA125) for endometriosis in symptomatic women: A multi-center study. European Journal of Obstetrics & Gynecology and Reproductive Biology 2017;210:102–7. https://doi.org/10.1016/j.ejogrb.2016.12.002. 	396 397 398 399
[18] Hirsch M, Duffy J, Davis C, Nieves Plana M, Khan K, on behalf of the International Collabo-	400
ration to Harmonise Outcomes and Measures for Endometriosis. Diagnostic accuracy of cancer	401
antigen 125 for endometriosis: a systematic review and meta-analysis. BJOG: An International Jour-	402
nal of Obstetrics & Gynaecology 2016;123:1761–8. https://doi.org/10.1111/1471-0528.14055.	403
[19] Shen A, Xu S, Ma Y, Guo H, Li C, Yang C, et al. Diagnostic value of serum CA125, CA19-9 and CA15-3 in endometriosis: A meta-analysis. J Int Med Res 2015;43:599–609. https://doi.org/10.1177/0300060515583076.	404 405 406
[20] Perricos A, Ashjaei K, Husslein H, Proestling K, Kuessel L, Obwegeser R, et al. Increased se-	407
rum levels of mBDNF in women with minimal and mild endometriosis have no predictive power	408
for the disease. Exp Biol Med (Maywood) 2018;243:50–6. https://doi.org/10.1177/1535370217742600.	409
[21] Wessels JM, Wu L, Leyland NA, Wang H, Foster WG. The brain-uterus connection: brain de-	410
rived neurotrophic factor (BDNF) and its receptor (Ntrk2) are conserved in the mammalian uterus.	411
PLoS One 2014;9:e94036. https://doi.org/10.1371/journal.pone.0094036.	412
[22] Herranz-Blanco B, Daoud E, Viganò P, García-Velasco JA, Colli E. Development and Valida-	413
tion of an Endometriosis Diagnostic Method Based on Serum Biomarkers and Clinical Variables.	414
Biomolecules 2023;13:1052. https://doi.org/10.3390/biom13071052.	415
[23] Tang Y, Wen M-B, Xiang R-M, Yang M-T, Shu B, Xu F, et al. Serum CA125 as a biomarker for	416
dysmenorrhea in adenomyosis. Int J Gynaecol Obstet 2023;163:131–9.	417
https://doi.org/10.1002/ijgo.14832.	418
[24] Chen Q, Li Y-W, Wang S, Fan Q-B, Shi H-H, Leng J-H, et al. Clinical Manifestations Of Ade-	419
nomyosis Patients With Or Without Pain Symptoms. J Pain Res 2019;12:3127–33.	420
https://doi.org/10.2147/JPR.S212117.	421

13	of	14
----	----	----

[25] Kil K, Chung J-E, Pak HJ, Jeung I-C, Kim JH, Jo HH, et al. Usefulness of CA125 in the differ- ential diagnosis of uterine adenomyosis and myoma. Eur J Obstet Gynecol Reprod Biol 2015;185:131–5. https://doi.org/10.1016/j.ejogrb.2014.12.008.	422 423 424
[26] Burghaus S, Drazic P, Wölfler M, et al. Multicenter evaluation of blood-based biomarkers for the detection of endometriosis and adenomyosis: A prospective non-interventional study. Int J Gy- naecol Obstet 2023.	425 426 427
[27] Park Y, Lee J-H, Hong DJ, Lee EY, Kim H-S. Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic dis- eases. Clin Biochem 2011;44:884–8. https://doi.org/10.1016/j.clinbiochem.2011.04.011.	428 429 430
[28] Moley KH, Massad LS, Mutch DG. Pelvic inflammatory disease. Correlation of severity with CA-125 levels. J Reprod Med 1996;41:341–6.	431 432
[29] Meden H, Fattahi-Meibodi A. CA 125 in benign gynecological conditions. Int J Biol Markers 1998;13:231–7. https://doi.org/10.1177/172460089801300411.	433 434
[30] Moss EL, Hollingworth J, Reynolds TM. The role of CA125 in clinical practice. J Clin Pathol 2005;58:308–12. https://doi.org/10.1136/jcp.2004.018077.	435 436
[31] Babacan A, Kizilaslan C, Gun I, Muhcu M, Mungen E, Atay V. CA 125 and other tumor markers in uterine leiomyomas and their association with lesion characteristics. Int J Clin Exp Med 2014;7:1078–83.	437 438 439
[32] Sharma D, Vinocha A. Benign Ovarian Cysts with Raised CA-125 Levels: Do We Need to Eval- uate the Fallopian Tubes? J Lab Physicians 2020;12:276–80. https://doi.org/10.1055/s-0040-1722547.	440 441
[33] Ataseven H, Oztürk ZA, Arhan M, Yüksel O, Köklü S, Ibiş M, et al. Cancer antigen 125 levels in inflammatory bowel diseases. J Clin Lab Anal 2009;23:244–8. https://doi.org/10.1002/jcla.20323.	442 443
[34] del Porto F, Aloe L, Laganà B, Triaca V, Nofroni I, D'Amelio R. Nerve growth factor and brain- derived neurotrophic factor levels in patients with rheumatoid arthritis treated with TNF-alpha blockers. Ann N Y Acad Sci 2006;1069:438–43. https://doi.org/10.1196/annals.1351.042.	444 445 446
[35] Tsavaris N, Mavragani CP, Dimitrios P. Rheumatoid arthritis: correlation between rheuma- toid factor levels and CA-125 tumour marker elevation. Ann Rheum Dis 2007;66:980. https://doi.org/10.1136/ard.2007.070052.	447 448 449
[36] Lai N-S, Yu H-C, Huang Tseng H-Y, Hsu C-W, Huang H-B, Lu M-C. Increased Serum Levels of Brain-Derived Neurotrophic Factor Contribute to Inflammatory Responses in Patients with Rheumatoid Arthritis. Int J Mol Sci 2021;22:1841. https://doi.org/10.3390/ijms22041841.	450 451 452
[37] Wang S, Sathish V, Freeman M, Thompson M, Pabelick CM, Prakash YS. Secreted Brain-De- rived Neurotrophic Factor and Asthma Severity. Am J Respir Cell Mol Biol 2016;54:297. https://doi.org/10.1165/rcmb.2015-0265LE.	453 454 455
[38] Shen Z, Zhu J, Yuan Y, Ren L, Qian M, Lin M, et al. The roles of brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) in predicting treatment	456 457

14 o	of 14
------	-------

remission in a Chinese Han population with generalized anxiety disorder. Psychiatry Res	458
2019;271:319–24. https://doi.org/10.1016/j.psychres.2018.08.111.	459
[39] Suliman S, Hemmings SMJ, Seedat S. Brain-Derived Neurotrophic Factor (BDNF) protein lev-	460
els in anxiety disorders: systematic review and meta-regression analysis. Front Integr Neurosci	461
2013;7:55. https://doi.org/10.3389/fnint.2013.00055.	462
[40] Satomura E, Baba H, Nakano Y, Maeshima H, Suzuki T, Arai H. Correlations between brain-	463
derived neurotrophic factor and clinical symptoms in medicated patients with major depression. J	464
Affect Disord 2011;135:332–5. https://doi.org/10.1016/j.jad.2011.06.041.	465
	100
[41] Rahmioglu N, Fassbender A, Vitonis AF, Tworoger SS, Hummelshoj L, D'Hooghe TM, et al.	466
World Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmoniza-	467
tion Project: III. Fluid biospecimen collection, processing, and storage in endometriosis research.	468
Fertil Steril 2014;102:1233–43. https://doi.org/10.1016/j.fertnstert.2014.07.1208.	469
	450
[42] Guerriero S, Ajossa S, Pagliuca M, Borzacchelli A, Deiala F, Springer S, et al. Advances in Im-	470
aging for Assessing Pelvic Endometriosis. Diagnostics (Basel) 2022;12:2960.	471
https://doi.org/10.3390/diagnostics12122960.	472
[43] Robinson AJ, Rombauts L, Ades A, Leong K, Paul E, Piessens S. Poor sensitivity of transvagi-	473
nal ultrasound markers in diagnosis of superficial endometriosis of the uterosacral ligaments. Jour-	474
nal of Endometriosis and Pelvic Pain Disorders 2018;10:10–7.	475
https://doi.org/10.1177/2284026518767259.	476
[44] Kitawaki J, Ishihara H, Koshiba H, Kiyomizu M, Teramoto M, Kitaoka Y, et al. Usefulness and	477
limits of CA-125 in diagnosis of endometriosis without associated ovarian endometriomas. Hum	478
Reprod 2005;20:1999–2003. https://doi.org/10.1093/humrep/deh890.	479
	480

